Please provide your email address to receive an email when new articles are posted on . The study, presented at ASCO Annual Meeting, evaluated intermittent vs. continuous panitumumab (Vectibix, Amgen) ...
An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer. A randomized phase 2, ...
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer In metastatic colorectal ...
Combining chemotherapy with one or two immune checkpoint inhibitors (ICIs) as second-line treatment for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma failed to improve progression ...
Prognostic factors for AKI include old age, low body mass index (BMI), proteinuria at baseline, as well as regimens containing bevacizumab, most notably, FOLFIRI + bevacizumab. The findings can help ...
Yakult Honsha has patented a method to predict the effectiveness of FOLFOX or FOLFIRI regimens for stage IV colorectal cancer treatment. By measuring copy number gains in specific chromosome regions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results